Cardiovascular and metabolic safety profiles of the fluoroquinolones

Expert Opin Drug Saf. 2012 Jan;11(1):53-69. doi: 10.1517/14740338.2011.624512. Epub 2011 Sep 30.


Introduction: Certain fluoroquinolones share similar indications of use. A comparison among Cardiovascular and metabolic (i.e., dysglycemia) safety profiles of the fluoroquinolones might be particularly useful for the prescribers' decision-making process as well as to hypothesize future researcher purposes.

Areas covered: A literature search was conducted using keywords apt to identify information on safety profile of the fluoroquinolones. Publications concerned with descriptive and etiological surveys were manually reviewed.

Expert opinion: Cardiac alterations and blood glucose impairments might be associated with any fluoroquinolone. However, the benefit/risk profile of these agents could be stratified for the single compounds. Several predisposing factors, such as diabetes, heart illnesses and their related pharmacotherapies, might exacerbate the risk of potentially serious adverse events. In this context, the opportunity of the more appropriate choice among different fluoroquinolones could be applicable.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use
  • Blood Glucose / drug effects*
  • Cardiovascular Diseases / chemically induced*
  • Diabetes Mellitus / epidemiology
  • Fluoroquinolones / adverse effects*
  • Fluoroquinolones / therapeutic use
  • Heart Diseases / complications
  • Humans
  • Risk Factors


  • Anti-Bacterial Agents
  • Blood Glucose
  • Fluoroquinolones